Thermo Fisher Scientific INC Form 4 insider transactions

Thermo Fisher Scientific Director R. Alexandra Keith acquired 66.02 phantom stock units valued at $473.36 each under the company's deferred compensation plan.

Thermo Fisher Scientific Director Karen S. Lynch acquired 66.02 phantom stock units through the company's deferred compensation plan.

Jennifer M. Johnson, a director at Thermo Fisher Scientific, acquired 66.02 phantom stock units through a deferred compensation plan.

Thermo Fisher Scientific Director Dion J. Weisler acquired 79.22 phantom stock units under the company's deferred compensation plan.

Thermo Fisher Scientific Inc. Chairman and CEO Marc N. Casper executed pre-planned sales of common stock totaling 10,000 shares after exercising stock options.

Thermo Fisher Scientific's Sr. VP and Chief HR Officer, Lisa P. Britt, disposed of common stock to cover tax withholding obligations.

Joseph R. Holmes, VP & Chief Accounting Officer at Thermo Fisher Scientific, reported the disposition of 116.626 shares of common stock for tax purposes.

Stephen Williamson, retiring Sr. VP and CFO of Thermo Fisher Scientific, disposed of common stock shares to cover tax liabilities.

Thermo Fisher Scientific's Executive Vice President, Michael D. Shafer, reported the disposition of 815.848 shares of common stock on February 28, 2026, for tax purposes.

Frederick M. Lowery, Executive Vice President at Thermo Fisher Scientific, reported planned sales of common stock totaling 896.968 shares under a Rule 10b5-1 plan.

Thermo Fisher Scientific's Sr. VP and CFO, Stephen Williamson, acquired 1,534 shares of common stock through a performance-based restricted stock unit award.

Thermo Fisher Scientific's Executive Vice President & COO, Michel Lagarde, acquired 2,231 shares of common stock through the vesting of a performance-based restricted stock unit award.

A Thermo Fisher Scientific executive acquired common stock and stock options as part of compensation, with vesting tied to performance and time.

Frederick M. Lowery, Executive Vice President at Thermo Fisher Scientific, reported changes in his beneficial ownership, including new performance-based restricted stock units and an adjustment to a prior award.

Thermo Fisher Scientific's SVP and General Counsel, Thomas B. Shropshire Jr., acquired common stock and stock options as part of a pre-arranged plan.

Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported significant equity awards, including performance-based restricted stock units and stock options, alongside an adjustment to a prior award.

Thermo Fisher Scientific's VP & Chief Accounting Officer, Joseph R. Holmes, reported the acquisition of common stock and stock options, alongside an adjustment to a previous performance-based award.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti acquired common stock and stock options through equity awards.

Thermo Fisher Scientific Inc. Chairman and CEO Marc N. Casper reported the acquisition of common stock and stock options through recent equity awards.

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti sold 400 shares of common stock for $541.20 per share under a pre-arranged trading plan.

Thermo Fisher Scientific Director Karen S. Lynch acquired 53.93 phantom stock units as part of the company's Deferred Compensation Plan for Directors.

Thermo Fisher Scientific Director R. Alexandra Keith acquired 53.93 phantom stock units valued at $579.45 each through the company's deferred compensation plan.

Thermo Fisher Scientific Director Scott M. Sperling acquired 73.35 phantom stock units as part of a deferred compensation plan.

Dion J. Weisler, a director at Thermo Fisher Scientific, acquired 64.72 phantom stock units valued at $579.45 each as part of a deferred compensation plan.

Thermo Fisher Scientific director Jennifer M. Johnson acquired 53.93 phantom stock units through a deferred compensation plan, increasing her beneficial ownership to 595.29 units.

Thermo Fisher Scientific Director Scott M. Sperling reported gifting 4,386 shares of common stock on December 10, 2025, reducing his direct beneficial ownership to 68,980 shares.

Thermo Fisher Scientific's Executive Vice President & COO, Michel Lagarde, exercised stock options and subsequently sold a portion of the acquired shares.

Thermo Fisher Scientific's Executive Vice President and COO, Michel Lagarde, exercised stock options and subsequently sold a portion of the acquired common stock for over $36 million.

Thermo Fisher Scientific's SVP and General Counsel, Thomas B. Shropshire Jr., disposed of 337.476 shares of common stock to cover tax withholding obligations.

Thermo Fisher Scientific Executive Vice President Frederick M. Lowery exercised stock options and subsequently sold shares totaling 13,825 shares under a pre-arranged 10b5-1 trading plan.